Xechem International Inc. (fka XKEM)

[lsd673]

Emmaus currently has one of the few sickle-cell treatments to ever reach late-stage trials. It is readying for the possible commercialization of the L-glutamine treatment that already has been fast-tracked for approval by the U.S. Food and Drug Administration.

'''''''''''''''''''''''''

McKinnell named to Emmaus board
Published 05/19/2010

Former Pfizer Inc. chief executive Henry McKinnell Jr. has joined the board at privately held Emmaus Medical Inc., which has been developing a remedy for sickle cell disease.

"His knowledge of the pharmaceutical industry and global experience will be invaluable as our company positions itself for significant near term growth," said Yutaka Niihara, head of Emmaus Medical, in a statement.

Emmaus currently has one of the few sickle-cell treatments to ever reach late-stage trials. It is readying for the possible commercialization of the L-glutamine treatment that already has been fast-tracked for approval by the U.S. Food and Drug Administration.

- Lee Howard

http://www.theday.com/article/20100519/BIZ02/305199959/-1/BIZ